NSRGY - Codexis Clinches Deal With Nestlé Health Science Eyes Up To $45M Milestone In EPI Treatment Breakthrough | Benzinga
Codexis, Inc. (NASDAQ: CDXS) entered a purchase deal with Nestlé S.A.(OTC: NSRGY) Nestlé Health Science for CDX-7108, a potential treatment for exocrine pancreatic insufficiency (EPI).
Under the terms of the agreement, Codexis will receive up to $45 million in potential milestone payments, including a $5 million upfront payment, as well as single-digit net-sales-based royalties.
Codexis will receive up to an additional $5 million if Nestlé Health Science exercises an option to ...